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Abstract: A polyelectrolyte complex system of chitosan-pectin nano- and microparticles was
developed to encapsulate the hormone insulin. The aim of this work was to obtain small
particles for oral insulin delivery without chemical crosslinkers based on natural and biodegradable
polysaccharides. The nano- and microparticles were developed using chitosans (with different
degrees of acetylation: 15.0% and 28.8%) and pectin solutions at various charge ratios (n+/n− given
by the chitosan/pectin mass ratio) and total charge. Nano- and microparticles were characterized
regarding particle size, zeta potential, production yield, encapsulation efficiency, stability in different
media, transmission electron microscopy and cytotoxicity assays using Caco-2 cells. The insulin
release was evaluated in vitro in simulated gastric and intestinal media. Small-sized particles
(~240–~1900 nm) with a maximum production yield of ~34.0% were obtained. The highest
encapsulation efficiency (~62.0%) of the system was observed at a charge ratio (n+/n−) 5.00.
The system was stable in various media, particularly in simulated gastric fluid (pH 1.2). Transmission
electron microscopy (TEM) analysis showed spherical shape particles when insulin was added to the
system. In simulated intestinal fluid (pH 6.8), controlled insulin release occurred over 2 h. In vitro
tests indicated that the proposed system presents potential as a drug delivery for oral administration
of bioactive peptides.
Keywords: chitosan; pectin; microparticles; nanoparticles; insulin; Caco-2 cells
1. Introduction
Chitosans are a family of polycationic aminopolysaccharides obtained from chemical or enzymatic
modification of chitin. Among the key properties of chitosan, the capacity to form self-assembled
electrostatic complexes with oppositely charged macromolecules, including polysaccharides, nucleic
acids or proteins is one the most important. Macromolecular complexation by electrostatic
self-assembly between chitosan and oppositely charged polymers can lead to highly stable colloidal
systems [1,2]. Maciel et al. developed a polyelectrolyte complex matrix formed between chitosan
and pectin to entrap a bioactive and hydrophilic compound (anthocyanin) that acts as a useful pH
indicator device [3]. Some characteristics of the particles can be modified to increase the encapsulation
efficiency (EE) of bioactive compound in the nanoparticles [4] such as the hydrodynamic diameter,
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morphology, zeta-potential (ζ-potential), and varying the ratio of either polymer or ionic crosslinker.
Among the advocated advantages of nanostructured particles are ability to form a material resistant to
acidic denaturation and enzymatic degradation, prolonging their residence time in the small intestine
and hence, modulating the kinetics of release and delivery of the bioactive payload [5,6]. Rao and
Geckeler [7], and Kreuter [8] have affirmed that nanoparticles could be defined as solid spherical
particles usually ranging between 10–1000 nm and, that they are more suitable for drug delivery
systems than microparticles. In this work, we have harnessed the capacity of electrostatic self-assembly
of chitosan and pectin to form biocompatible macromolecular complexes that can be used in drug
delivery. Pectin is a natural, low toxicity and polyanionic polysaccharide extracted from the cell walls
of most plants, such as apples, oranges and pears. As chitosan does, pectin also exhibits material and
bioactive properties. Chemically, it is a branched heteropolysaccharides, which consist predominantly
of linear chains of partially methyl-esterified (1,4)-α-D-galacturonic acid residues [9].
The International Diabetic Federation reported that 366 million people were affected by diabetes
in 2011 and estimated that this number will increase to 552 million in 2030 [10,11]. Diabetes is one
of the most lethal diseases due to its high prevalence and secondary effects. The World Health
Organization [12] reported that it is responsible for thousands of deaths per year worldwide. Insulin,
a protein composed by 51 amino acid residues, is the most common and effective drug used to control
diabetes [13,14]. Peptides and proteins have been used as biopharmaceuticals due to their high activity,
specificity and effectiveness compared to conventional drugs [10]. However, suitable formulations
intended for oral administration based on proteins are still under development. During their transit
through the gastrointestinal tract, drug molecules encounter several metabolic and physicochemical
barriers. These include the harsh acidic environment of the stomach, extensive enzymatic degradation
by various proteolytic enzymes, poor intestinal absorption, mucus clearance and overcoming the
epithelial cell barrier [15]. The combination of these obstacles limits the systemic absorption of drugs
and consequently, their therapeutic functions [16]. The use of oral formulations to deliver insulin with
high bioavailability has been a subject of intense research efforts However, up to now, no successful
formulations showing high insulin bioavailability have been marketed.
The use of biocompatible and biodegradable polymeric nano- and microparticles have been
described as a promising strategy for oral administration of proteins such as insulin and peptides [17],
providing a stable environment for the encapsulated drug [18]. An increasing number of studies have
shown that polymeric nano- and microparticles are effective as drug carriers. Mukhopadhyay et al.
developed self-assembled chitosan–insulin nanoparticles for oral insulin delivery and evaluated their
efficiency using an in vivo diabetic model [16]. Al-Azi et al. [19] investigated insulin encapsulation,
as a model drug, using high molar mass pectin–chitosan coacervates. Mukhopadhyay et al. developed
chitosan–alginate nanoparticles for oral insulin administration by ionotropic pre-gelation of alginate
to entrap insulin within the inner core, followed by polyelectrolyte complexation with chitosan [20].
Andreani et al. found evidence that silica nanoparticles coated with hydrophilic polymers (chitosan,
sodium alginate and polyethylene glycol) can function as mucoadhesive carriers for oral insulin
administration [21]. Further, Chronopoulou et al. developed an optimised drug delivery carrier
(chlorhexidine) for oral mucosa use, able to deliver bioactive molecules in situ, using chitosan-based
nanoparticles [22]. In turn, Zhang et al. prepared a novel polyelectrolyte complex based on cationic
chitosan and anionic poly(2-acrylamide-2-methyl-propanesulfonic acid) using a polymer–monomer
pair reaction system to form nanoparticles [23]. Our study complements previous works, by expanding
our understanding on biopolymer-based carriers intended for oral insulin delivery. To this end,
we developed insulin-loaded nano- and microparticles based on pectin and chitosan of low molar
mass and two distinct degrees of acetylation (DA). We then studied the influence of the composition and
DA of chitosan on the size distribution, ζ-potential, production yield, stability in different biological
media, insulin EE, morphology by transmission electron microscopy (TEM), cytotoxicity by Caco-2
cells and insulin in vitro release.
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2. Results and Discussion
2.1. Chitosan and Pectin Characterisation
The degrees of acetylation of chitosan (Heppe medical chitosan) HMC+ 85/5 and HMC+ 70/5
were 15.0% and 28.8%, respectively. The intrinsic viscosity ([η]) and molar mass of HMC+ 15 were
179.4 mL·g−1 and 2.74 × 104 g·mol−1, respectively, and 124.2 mL·g−1 and 1.75 × 104 g·mol−1,
respectively, for HMC+ 70/5. The degree of esterification (DE) of pectin was 68.2%, being classified as
a highly methoxylated pectin and the [η] and molar mass of this polysaccharide were 429.5 mL·g−1
and 1.01 × 105 g·mol−1, respectively. The DA of chitosan, DE of pectin, as well as the polymer
molar mass, are known to be important polymer characteristics to consider when forming nano- and
microparticles [24–26].
2.2. Nano- and Microparticles Characterisation
Preliminary tests were developed to evaluate the nano- and microparticle formation over a
wide range of charge ratio (n+/n−) (varying from 0.10 to 5.00). The optimal formulations were
chosen, namely with excess pectin charge and excess chitosan charge. The formation of nano-
and microparticles was verified visually from the solution turbidity and the absence of polymeric
agglomeration, under all the tested conditions. These included various charge ratios (n+/n−),
total charge (1.0 or 2.0 × 10−6 M), pH (4.0, 5.0, 5.5 and without pH adjustment) and DA of chitosan
(15.0% and 28.8%). Particles were formed using chitosan with DA of 15.0% and without adjusting the
pH at charge ratios (n+/n−) 2.00, 4.00 and 5.00. Using chitosan with 28.8% DA, the best charge ratios
(n+/n−) to form particles were 1.33, 2.00, 4.00 and 5.00.
The behaviour of each polyelectrolyte solutions and the best pH range to obtain further nano-
and microparticles were assessed for chitosan (DA 15.0% and 28.8%) and pectin (Figure 1). To this end,
it was measured the pH-dependence of the ζ-potential of aqueous solutions of both polyelectrolytes
(chitosan and pectin) in the pH range evaluated (1.0–8.0).
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Figure 1. Variation of the ζ-potential (zeta-potential) with pH for chitosan and pectin solutions prepared
in 100 mM NaCl (as in legend) at 25 ◦C.
It is noted in Figure 1 that no major change in ζ-potential occurred in the pH range of ~2.0 to
~5.0. Beyond pH 5.0, the ζ-potential decreased from ~+27.0 to ~+7.0 mV for both chitosan solutions.
These results are consistent with the reported intrinsic pKo of chitosan (~6.1) [27,28]. At pH < pKo,
the amino groups of chitosan are predominantly protonated, which confers the molecule a polycationic
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character. In turn, for pectin the surface net charge remained negative (ζ-potential = ~−25.0 mV)
at pH > 4.5. However, at pH < 4.5, the ζ-potential values decreased monotonically until nearly
reaching zero at pH 1.5. The ζ-potential is defined as the electrical potential at the hydrodynamic shear
plane with respect to that of the solvent [29]. In our work, we have measured ζ-potential the only
as an indication of the charge state of the polyelectrolytes at the given working pH. Measurements
of ζ-potential as a function of ionic strength have been used by Abodinar et al., to estimate the
conformation and chain flexibility of polyelectrolytes in dilute solution and their dependence on ionic
strength [30]. Although the ζ-potential parameter offers a close picture of the net degree of ionization
of the polyelectrolyte in solution at a given pH, the fact that it is sensitive to the structural and
conformational aspects of the polyelectrolyte, it cannot be regarded as a surrogate of potentiometric
nor conductimetric measurements.
The ζ-potential pH-dependence observed for pectin agrees with the reported pKa of 3.5–4.5 [31].
At pH < 4.5, the anionic character of pectin is weakened due to the dissociation of the carboxylic
groups of the pectin structure [32]. In preliminary tests, we observed that when the chitosan–pectin
complexes were formed at pH ~5.0, agglomeration occurred. Coimbra et al. have suggested that the
available charges at low pH could decrease the agglomeration process of the polymer solution [26].
2.3. Zeta-Potential and Particle Size Distribution Analysis
It was expected that pectin’s carboxylate groups would interact electrostatically with oppositely
charged amino functions of chitosan to form nano- and microparticles by polyelectrolyte complexation
under controlled conditions to form stabilised colloidal particles. The ζ-potential (proportional to the
surface charge density) values of the obtained particles are shown in Figure 2. Microparticles with
size less than ~2500 nm were produced using chitosan with DA of 15.0% at 1.0 × 10−6 M total charge
(Figure 2a) and charge ratios (n+/n−) 0.25 and 5.00, with a polydispersity index of 0.25 ± 0.06 and
0.40 ± 0.06, respectively, in good keeping with previously published values [24,33]. Based on the
ζ-potential values (Figure 2a), we reasoned that the charge ratios (n+/n−) below 1.00 presented negative
values, consistent with an excess of pectin in the nano- and microparticles system. At charge ratios
(n+/n−) > 1.0, the resultant system exhibited a positive ζ-potential, in expected agreement with excess
chitosan. Increasing the total charge (n+ + n−) from 1.0 × 10−6 to 2.0 × 10−6, produced larger particles
at charge ratio (n+/n−) 0.25 and 5.00, with average diameters of ~2500 and ~5000 nm, respectively.
There was a very close similarity between the results observed for the systems with chitosan of DA
15.0% and those with chitosan of DA 28.8%. Microparticles with size less than ~1500 nm were obtained
at charge ratio (n+/n−) 0.25 (Figure 2c,d). Negative ζ-potential values (Figure 2c,d) were evidenced
for charge ratio (n+/n−) < 0.75, indicating an excess of pectin in the particle solution. As observed
using chitosan with DA 15.0%, at charge ratio (n+/n−) > 1.0, the particles invariably attained a positive
surface charge, associated with the stoichiometric surplus of chitosan. The ζ-potential dependence on
charge ratio (n+/n−) obtained for the four analysed systems revealed that regardless of chitosan DA
(either 15.0% or 28.8%) and the total concentration, the complexes were fully compensated (i.e., when
the ζ-potential is zero) at charge ratio (n+/n−) very close to the stoichiometric point ((n+/n−) ~1.0).
These results are in close agreement with those obtained in a previous study focused on chitosan
(DA ~20%; molar mass ~230 kg·mol−1)/polyguluronate polyelectrolyte complexes [34]. In these
systems, the equivalence point, as determined by conductimetric titrations, was also found at an
equivalent charge ratio (n+/n−) ~1.0. From the above experiments, we selected four systems for
subsequent studies of insulin loading, namely, the two chitosans (DA 15.0% and 28.8%), two charge
ratios ((n+/n−) 0.25 and 5.00) and 1.0 × 10−6 M total charge.
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Figure 2. Variation of the Z-average hydrodynamic diameter and ζ-potential with charge ratio (n+/n−)
of particles comprised by chitosan of different DA and pectin at pH 2.7 and 25 ◦C for systems with:
(a) total charge 1.0 × 10−6 M, chitosan degree of acetylation (DA) 15.0%; (b) total charge 2.0 × 10−6 M,
chitosan DA 15.0%; (c) total charge 1.0 × 10−6 M, chitosan DA 28.8; and (d) total charge 2.0 × 10−6 M,
chitosan DA 28.8%.
2.4. Production Yield of Nano- and Microparticles
The production yield of nano- and microparticles loaded with insulin or unloaded (blanks) was
calculated based on the complex mass obtained after lyophilisation and the initial mass of the pectin,
chitosan, N Cl and nsulin used (Table 1).
Table 1. Particle size, ζ-potential and production yield of chitosan-pectin unloaded or loaded with
insulin prepared at different charge ratios (n+/n−) and comprising chitosans of varying degree
of acetylation.
Analysis Insulin
Chitosan DA 15.0% Chitosan DA 28.8%
Charge Ratio (n+/n−) Charge Ratio (n+/n−)
0.25 5.00 0.25 5.00
Particles size (d, nm)
Blank 2530 ± 384 aA 2618 175 aA 1875 ± 135 aA 2011 ± 266 aA
Loaded 1351 ± 384 aB 1522 ± 346 aB 964 ± 32 aB 2510 ± 107 bB
ζ-potential (mV) Blank −22.5 ± 0.8
aA +35.0 ± 1.4 bA −23.4 ± 0.9 aA +27.2 ± 1.4 bA
Loaded −22.5 ± 2.5 aA +33.2 ± 2.3 bA −22.4 ± 2.4 aA +28.6 ± 2.0 bA
Production yield (%) Blank 23.8 ± 1.1
aA 18.9 ± 3.0 bA 22.6 ± 0.6 aA 23.7 ± 3.3 aA
Loaded 27.2 ± 3.9 aA 33.8 ± 4.3 aB 24.3 ± 2.0 aA 22.4 ± 2.0 aA
a,b: Average of different letters in the same line for the same analysis and type of chitosa differ statistically (p < 0.05)
by Tukey test. A,B: Average of different letters in the same column for the same analysis and type of chitosan differ
statistically (p < 0.05) by Tukey test.
Inspection of Table 1 shows that the nano- and microparticles average hydrodynamic diameter
was smaller after insulin loading, except for chitosan with a DA 28.8% at charge ratio (n+/n−) 5.00.
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This could indicate that the substitution of pectin by insulin at equivalent charge concentration
considerably changed the particle size. An electrostatic interaction between the bioactive polypeptide
and polymers (chitosan and pectin) could promote the small particles formation in solution, avoiding
agglomerates of particles with greater size. The process of insulin addition to the nano- and
microparticles was efficient, as there were no significant differences (p < 0.05) between the ζ-potential
of the blank and insulin-loaded formulations.
Overall, higher production yields were obtained for the nano- and microparticles containing
insulin than the blank ones. Particularly, in the formulations based on chitosan with DA 15.0% and
charge ratio (n+/n−) 5.00, for which the increment in yield was ~100% (18.9% to 33.8% for blank and
insulin-loaded systems, respectively). In the other systems studied, the insulin loading only moderately
increased the yield (less than 10%). In general, our yield values agree with those of previous studies
on chitosan-tripolyphosphate nano- and microparticles for drug delivery that found production yields
ranging from 38–51% [35], 12–48% [36], and 24–84% [37].
2.5. Stability of Insulin-Loaded Nano- and Microparticles
The stability of insulin-loaded nano- and microparticles was evaluated by analysing the evolution
of the particle size upon incubation in 150 mM NaCl (pH 7.4), minimal essential medium (MEM, pH 7.4),
simulated gastric fluid (SGF, pH 1.2) and simulated intestinal fluid (SIF, pH 6.8), at 37 ± 1 ◦C for 24 h
(Figure 3). As shown in Figure 3a, the particle size obtained from chitosan with DA 28.8% and charge
ratio (n+/n−) 5.00 increased 4-fold after incubation in 150 mM NaCl for 24 h (from 5.0 to 20.0 µm).
In contrast, the particle size obtained from chitosan with DA 28.8% and charge ratio (n+/n−) 0.25 (i.e.,
a surplus of negatively charged pectin) was notably smaller and remained stable at 24 h. Particles
of smaller size tend to be more stable than larger particles against aggregation under physiological
conditions, and are known to be also more effective to promote the absorption process of proteins
through the intestinal epithelium [20,23]. Further, the particle size is an important characteristic
to determine the absorption process, distribution, and in vivo performance of nanoparticles; it also
influences the drug loading capacity and in vitro release characteristics of nanoparticles. In general,
nanoparticles exhibit higher cellular uptake efficiency than do the larger size microparticles [14,21].
Nanoparticles with a particle size < 100 nm administered orally are known to be efficiently taken up
in Peyer’s patches, and then absorbed into systemic circulation [38]. The evolution of the particle
size in physiological conditions (150 mM NaCl and pH 7.4) is an indicator of the stability of colloidal
particles during exposure to physiological isotonic conditions [39]. Interestingly, Lu et al. also observed
that insulin-loaded polyelectrolyte complex nanoparticles of poly(glycerol methacrylate)s (cationic
polymer) increased in size from 250 to 3000 nm upon increasing the NaCl concentration from 0.020 to
0.100 M [40]. They attributed this behaviour to the salt action, which could facilitate the polysaccharide
complexation, thus resulting in larger particles size.
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Figure 3. Evolution of the ζ-average hydrodynamic diameter of insulin-loaded particles comprised by
chitosans of varying DA and pectin mixed at different charge ratio (n+/n− as shown in labels) during
incubation at 37 ± 1 ◦C for 24 h in: (a) 150 mM NaCl (pH 7.4); (b) MEM (minimal essential medium,
pH 7.4); (c) SGF (simulated gastric fluid, pH 1.2) and (d) SIF (simulated intestinal fluid, pH 6.8).
In general, the systems showed greater stability when incubated in MEM than in NaCl (Figure 3b).
The average particle size in this instance was also significantly smaller (~300–~1600 nm). At 24 h
incubation, the particle size remained below 700 nm, except for the formulation using chitosan with
DA 28.8% and charge ratio (n+/n−) 0.25 that exhibited overall larger particle sizes after incubation.
In previous studies, it was observed that chitosan-based nanocapsules obtained from chitosans of
varying DA, were table in cell culture medium, particularly t se comprised by chitosa of high DA
and low molecular weight [41]. We have argued that the hydrophilic nature of chitosan t th surface
of these systems results in a stabilization mechanism based on short-range repulsive hydratio forces.
Russo et al. evaluated the stability of chitosan nanoparticles loaded with foscarnet, an antiviral agent,
in phosphate buffered saline (PBS) at 37 ◦C and observed a gradual increase in particle size during the
first 5 h [42]. To minimise this behaviour, the authors suggested adding a crosslinker (glutaraldehyde)
to a particle preparation. This study also highlights the role of the polymers mobility on the overall
colloidal stability at the surface of the particles. These effects seen previously by Russo et al. on the
polymers mobility could also be observed in the chitosan/pectin complexes [42]. The behaviour of
insulin-loa ed nano- nd microparticles was f rther evaluated in SGF (Figure 3c) and SIF (Figure 3d).
The particle size upon incubation in SGF remained within 240–420 nm, and this persisted for 24 h.
Nano- and microparticles obtaine at charge ratio (n+/n−) 0.25, independent of chitosan’s DA,
showed particle diameters ~1000 nm after incubation in SIF. Increasing the charge ratio (n+/n−) from
0.25 to 5.00 (i.e., excess of positive charges from chitosan), the particles only remained stable for 3 h.
Beyond this time, the particle size gradually increased upon incubation for up to 24 h. At pH close to
neutrality, such as under SIF conditions, chitosan is practically non-ionised [27], which may explain
the instability of the systems with excess chitosan. The increase in particle size can be attributed to
aggregation of the particles rather than to swelling, as evidenced dynamic light scattering (DLS, results
not shown).
Our results agr e well with those of Bagre et al. who stud ed controlled deliv ry of enoxaparin
from chitosan nanoparticles coated with alginate and found that the particles were not stable upon
incubation in SIF (pH 7.4) [43]. They attributed this to the sensitivity of chitosan at the physiological
pH of intestinal fluid after the dissolution of the alginate coat. Luo et al. evaluated the stability of lipid
nanoparticles coated with chitosan intended for oral application, observing adequate results under
acidic conditions [44]. The stability of insulin-loaded chitosan microspheres was evaluated under
gastric pH, verifying that the insulin was protected from enzymatic degradation in this medium [45].
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2.6. Insulin Encapsulation Efficiency (EE)
The EE of the insulin-loaded chitosan-pectin nano- and microparticles with different charge ratios
(n+/n−, 0.25 and 5.00) and DA of chitosan (15.0% and 28.8%) are shown in Table 2. An EE of 34–37% of
insulin was achieved for systems with charge ratio (n+/n−) 0.25. The EE was further improved (62%)
for systems with charge ratio (n+/n−) 5.00, independent of DA of chitosan. We reason that the excess of
positive chitosan charges considerably influenced the insulin loading of the nano- and microparticles.
Table 2. Encapsulation efficiency (EE) of insulin at the nano- and microparticles prepared in different
charge ratios (n+/n−) and degree of acetylation (DA) of chitosan.
Formulation Charge Ratio (n+/n−) DA (%) EE (%)
1 0.25 15.0 36.6 ± 6.6 a
2 5.00 15.0 62.2 ± 3.1 b
3 0.25 28.8 34.2 ± 8.1 a
4 5.00 28.8 61.9 ± 0.5 b
a,b: Average of different letters in the same column differ statistically (p < 0.05) by Tukey’s test.
Ideal nanoparticulate systems must have a high drug EE [46]. Different bioactive molecules,
particularly biologics (e.g., enzymes, peptides, monoclonal antibodies), should maintain their bioactive
conformation as to display the desired bioactive effects in vivo. Electrostatic interactions between the
acidic groups of insulin and/or anionic polymers and amino groups of chitosan have important effects
in the EE of insulin in chitosan-tripolyphosphate nanoparticles [47].
In previous studies focused on insulin-loaded nanoparticles comprised by polyelectrolyte
complexation of chitosan and alginate and concomitantly by ionic gelation with tripolyphosphate,
it was determined insulin encapsulation efficiency of 41–52% [48]. The chitosan/insulin mass ratio
in these studies was fixed at 2.0 and in the present work varied between 0.4 and 0.5 (depending
on DA of chitosan). However, in the mentioned studies they did not address the influence of the
charge stoichiometry of chitosan to alginate, as we have done in the present work. It is clear from our
results, that the composition of the system, determined by the proportional amount of chitosan is what
governs the net amount of associated insulin. We propose that the association of insulin is mediated
predominantly by electrostatic interactions between oppositely charged chitosan and insulin. The fact
that the overall production yield was lower for the systems comprised by the chitosan of lower charge
density (i.e., DA 28.8%) seems consistent with the idea that insulin is associated at the expense of
the complexation of chitosan with pectin, as we have observed before in the chitosan–alginate–TPP
(tripolyphosphate) nanoparticles [49].
Many studies have addressed the development of nanoparticles for oral delivery of insulin.
Pan et al. found that chitosan nanoparticles can improve the intestinal absorption of insulin in
alloxan-induced diabetic rats in up to 80% EE [49]. Bayat et al. reported that the insulin-loaded
nanoparticles formed from chitosan and its derivatives (triethyl- and dimethylethylchitosan) had an EE
between 84–90% [46]. Mukhopadhyay et al. produced self-assembled chitosan-insulin nanoparticles
and obtained an insulin EE around 85% [16]. Al-Azi et al. found relatively lower values of EE,
namely 5%, in insulin-loaded nanoparticles produced by complex coacervation between chitosan
and pectin [19]. They attributed such low insulin association capacity to the low coacervation rate
between the high molar mass polymers. Other studies have focused on the use of chitosan-based
polyelectrolyte complex systems for drug delivery. Jardim et al. synthesised chitosan-chondroitin
sulphate nanoparticles curcumin-loaded and found EE of curcumin ranged from 62.4 ± 0.61%
to 68.3 ± 0.88% [5]. Zhang et al. prepared a polyelectrolyte complex based on chitosan and
poly(2-acrylamide-2-methylpropanesulfonic acid) using a polymer-monomer pair reaction system and
found the EE of doxorubicin ~61–64% [23].
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2.7. Transmission Electron Microscopy
Images of nano- and microparticles non-loaded or insulin-loaded were recorded by transmission
electron microscopy (TEM) and analysed in terms of morphology and surface topology. Representative
images of the systems formulated using chitosan DA 28.8% at two different charge ratios (n+/n−,
0.25 and 5.00) are shown in Figure 4. Very similar micrographs were recorded for systems comprised by
chitosan DA 15.0% (results not shown). It was interesting to notice that the systems loaded with insulin
revealed a more spherical morphology (Figure 4c,d) than the corresponding blank ones, independently
of the charge ratio (n+/n−). Insulin-loaded chitosan particles presenting spherical shape and smooth
surface have also been found in previous studies [16,48]. The range of particle size observed in the
TEM images in all cases seems smaller compared to those obtained from DLS analysis. This could be
the expected consequence of the larger abundance by number of smaller particles over the larger ones,
hence these are more likely to be better imaged in suitable windows of the grid during TEM. Also,
the hydrodynamic diameter of freshly prepared nano- and microparticles measured by DLS may be
expanded due to swelling, whereas such effect is likely to be abrogated during the preparation of the
specimens for TEM [20].
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The reduction of MTT, a yellow tetrazolium salt, occurs by metabolically competent mitochondria.
After reduction, a violet formazan dye is formed, and the metabolic competence (assumed to be
directly proportional to the cell viability) can be quantified spectrophotometrically by comparing
the results to the corresponding positive and negative controls [53]. Caco-2 cells are frequently used
as representative cells of the human intestine due to their capacity to spontaneously differentiate
after 3–4 weeks into highly polymerised phenotypes [54] with functional tight junctions in porous
membranes [55].
In this study, the in vitro cytotoxicity of the chitosan-pectin nano- and microparticles at different
concentrations was evaluated by MTT tests (Figure 5). Blank nano- and microparticles showed cell
viability values above 90% (Figure 5a) and 80% (Figure 5c), irrespective of the chitosan’s DA and the
chitosan–pectin charge ratio (n+/n−). No dose-response effect was observed upon treating the cells
with particle concentrations from 5–100 µg·cm−2. Cell viability did not decrease even after incubation at
37 ◦C for 4 h. In all the blank formulations, the particles neither showed any particular cytotoxicity nor
influenced the normal growth of Caco-2 cells within the dose range studied (≤100 µg·cm−2). However,
the insulin-loaded particles decreased the cell viability, which was influenced by the chitosan’s DA
(Figure 5b,d). While moderate decreases (75–95%) in cell viability were observed for the systems
using chitosan with DA 15% (Figure 5c), the decrease was notably more evident (55–70%) in the
treatments comprising chitosan DA 28.8% (Figure 5d) at both the chitosan/pectin equivalent charge
ratios (n+/n−) studied.
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Figure 5. Cell viability (MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay) of
Caco-2 cells after treatment (4 h at 37 ± 0.1 ◦C) varying concentrations of nano- and microparticles
at different charge ratio (n+/n−) (as in figure legends). (a) Blank (unloaded) particles, chitosan DA
15.0%; (b) Insulin-loaded, chitosan DA 15.0%; (c) Blank (unloaded) particles, chitosan DA 28.8% and
(d) Insu in-loaded, chitosan DA 28.8% (values represent average and standard deviations of three
biological replicates).
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The significantly accentuated decrease in cell viability observed for the insulin-loaded systems
using chitosan with DA 28.8% compared to chitosan with DA 15.0%, reveals that the DA of chitosan
was an important characteristic that influenced the cytocompatibility of these systems. An overall
lower cell viability and a dose-response at increasing concentrations (from 5.0 to 100 µg·cm−2) were
observed for the particles using chitosan with DA 28.8% than for those comprising chitosan of DA
15.0%. This could be attributed to the role of insulin as an endogenous hormone that can interfere with
normal cell metabolism [50]. The differences in cell viability associated with the DA of chitosan could
stem from the greater intracellular delivery achieved by the particles using chitosan with DA 28.8%
than the more highly-charged chitosan.
Previous studies have addressed the cytocompatibility of chitosan-based nanoparticle
formulations. Loretz and Bernköp-Schnurch proposed that in general, the decrease in Caco-2 cell
viability upon treatment with chitosan (low viscosity and DA 19.0%) could result from electrostatic
interactions between chitosan nanoparticles and the cell membrane [56]. This was confirmed by
Soliman et al. who reported a simple and bioinspired nanoparticulate system by preparing hydrocaffeic
acid-chitosan conjugates loaded with bovine serum albumin [39]. They found accentuated cell viability
decreases in the presence of the drug. Biswas et al. developed and characterized sodium alginate
coated chitosan (42, 74 and 106 kDa) nanoparticles, in which the measles antigen was entrapped
and found no significant difference in cell viability [57]. In another study, Jia et al. studied the
transport of chitosan (14% DA) nanoparticles across Caco-2 cell monolayers [58]. They found that the
cytotoxicity was mainly influenced by the molar mass of chitosan (200 kDa) and its cationic charge
density, promoting a high degree of interaction between chitosan and the cell membrane. Sadeghi
et al. evaluated the permeation of insulin-chitosan nanoparticles through a Caco-2 cell monolayer
using chitosan and its derivatives (trimethyl-, dimethylethyl-, diethylmethyl- and triethylchitosan)
and concluded that the polymers did not exert any cytotoxicity (less than 1.0% dead cells) [59]. Similar
results were reported by Zhang and Zhao who investigated chitosan nanoparticles and found cell
viability values above 84.0% [36].
2.9. Insulin Release: In Vitro Tests
Insulin release from nano- and microparticles prepared using different chitosans (DA 15.0% and
28.8%) at charge ratio (n+/n−) 5.00 (selected from the higher EE values) was studied in SGF (pH 1.2)
(Figure 6a) and SIF (pH 6.8) (Figure 6b) for 120 min, respectively. The chitosan DA did not influence the
process of insulin release, presenting similar behaviour under both conditions. In SGF, initially, a small
amount of insulin was released (~2%) (Figure 6a), followed by a controlled release that after 120 min
did not exceed ~13%. Note that the overall release of insulin in SGF (pH 1.2) was much lower than that
in simulated intestinal fluid (pH 6.8). This is believed to be caused by the weak electrostatic interaction
between the insulin, bearing a highly positive net charge, and the polyelectrolytes on the surface.
Further, insulin released from nano- and microparticles comprising the two chitosans (DA 15.0%
and 28.8%) in conditions that simulated the human intestine (pH 6.8) was controlled (Figure 6b) and
attained a maximum of 89.0% after 120 min.
The insulin delivery from nano- and microparticles carried out in SIF (Figure 6b) showed a
controlled and slightly prolonged insulin release, amounting to 87.0–89.0% of its initial amount. This
could be due to the strong interaction between the alkaline solvent and positively charged chitosan
shell, facilitating the penetration of the solvent towards the pectin core. In contrast, the positive charges
from chitosan and the tight pectin network could help to retain the insulin at pH 1.2 and protect the
encapsulated insulin against proteolytic degradation in the stomach [16]. The behaviour of insulin
release under acidic conditions is in accordance with previous studies [21,43,60]. However, the rapid
insulin delivery at pH 6.8 was an unexpected result.
For the measles antigen entrapped in coated and uncoated chitosan nanoparticles, Bagre et al.
found that the antigen was rapidly delivered (40.0% in 2 h) in SGF using the uncoated nanoparticles,
which was associated to the high solubility of chitosan at low pH [43]. Biswas et al. observed rapid
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antigen delivery (~20.0%) from chitosan nanoparticles in PBS (pH 7.4) at 3 h [57]. The authors attributed
this to a weak ionic interaction between the bioactive and chitosan, which could be easily desorbed in
an ionic environment. Mukhopadhyay et al. prepared chitosan-alginate nanoparticles to incorporate
insulin and evaluated the delivery process in gastric (pH 1.2) and intestinal (pH 6.8 and 7.4) media [21].
Rapid delivery of insulin (26.7%) was observed in the gastric medium after 2 h, which was attributed
to weak interactions between insulin and the poly-electrolytes. In SIF, however, a slow and modulated
delivery of insulin (79.0–84.0%) was found at 24 h.
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Figure 6. Percentage cumulative of insulin release from nano- and microparticles prepared using
chitosan of different DA and pectin at charge ratio (n+/n−) 5.00 during incubation for 120 min at
37 ± 0.1 ◦C in: (a) Simulated gastric fluid (pH 1.2) and (b) Simulated intestinal fluid (pH 6.8).
3. Materials and Methods
3.1. Materials
Two high-purity, research grade chitosan samples (chitosan 85/5 Nr. 23500, lot 212-300811-03,
herein referred to as sample “HMC+ 15”, and chitosan 70/5 Nr. 23200, lot 212-111111-03, herein
referred to as sample “HMC+ 28.8”), were purchased from Heppe Medical Chitosan GmbH (Halle,
Germany) and used as received; pectin (from citrus peel) with a high DE (GENU® 105 rapid set, lot
LI03024) was from CPKelco (Limeira, Brazil); and recombinant human insulin (molar mass of 5.7 kDa,
lot 11D762J) was from SAFC (Lenexa, KS, USA). All reagents were of analytical grade. Ultrapure
MilliQ water was used throughout.
3.2. ethods
. . . t r i ti f t
c itosan sa ples was determined by 1H-NMR spectroscopy, per the procedure of
Lavertu et al. [61], using a DRX 50 spectrometer (Bruker, Fal an e , fl
20 ◦ for 4 , ili
ft 2 ). e spectra er ac ir
◦C. The DA (%) was calculated using integrals of the peak of the proton of deacetylated monomer
(H1D) and of the peak of the three protons of the acetyl group (H-Ac), i.e., DA (% = 100− [[H1D/(H1D
+ -Ac/3)] × 100].
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3.2.2. Determination of Intrinsic Viscosity ([η]) and Molar Mass Estimation of Chitosans
The [η] of the chitosan samples was determined according to Rinaudo et al. [62]. Briefly, HMC+
15 chitosan solutions (1.25, 1.50, 1.75, 2.00 and 2.50 mg·mL−1) and HMC+ 28.8 solutions (2.00, 2.50,
3.00, 4.00 and 5.00 mg·mL−1) were prepared in 0.3 M AcOH/0.2 M AcONa. The relative viscosity
was measured using a model AMVn automatic capillary rolling ball microviscometer (Anton Paar,
Scharnhausen, Germany) at 25 ± 0.2 ◦C (four determinations per concentration). The [η] (mL·g−1) was
estimated by extrapolation and averaging from the Huggins (Equation (1)), Kraemer (Equation (2))
and Solomon-Ciuta equations (Equation (3)):
ηsp
C
= [η] + [η]2kHC (1)
where ηspC is the reduced viscosity (mL·g−1), kH is the Huggins’ coefficient and C is the polymer
concentration (g·mL−1).
ln([η]rel)/C = [η] + [η]
2kKC (2)
where ln([η]rel)/C is the inherent viscosity, kK is the Kraemer’ constant and C is the polymer
concentration (g·mL−1).
[η] =
[
2
(
ηsp − ln ηred
)]1/2/C (3)
where ηsp is the specific viscosity, ηred is the reduced viscosity and C is the polymer concentration
(g·mL−1).
The viscosimetric mean average molar mass, M, was then estimated from the [η] value using
Mark-Houwink-Sakurada relationship (Equation (4)):
[η] = KMα (4)
where, K = 7.4× 10−2 and 7.6× 10−2 (mL·g−1) for HMC+ 28.8 and HMC+ 15, respectively, and α = 0.76
for both [60].
3.2.3. Determination of the Degree of Esterification of Pectin
In accordance with Rosenbohm et al. 5.0 mg of pectin was dissolved in 0.8 mL of D2O under
magnetic stirring at 55–60 ◦C for 1 h, frozen at −20 ◦C for 24 h, lyophilised and then 1.0 mL of
D2O added and the mixture stirred until fully dissolved [63]. The 1H-NMR spectra were acquired
at 25 ◦C on a DRX 500 model spectrometer (Bruker). The DE (%) is defined as the number of ester
groups compared to the total number of carboxylic acid and ester groups. The DE was determined
by comparing integrals of H-5 adjacent to esters (ICOOMe) to the sum of the integrals of H-5 adjacent
to esters (ICOOMe) and H-5 adjacent to carboxylates (ICOO−). Due to the proximity (or overlap) of the
signals for H-1 and H-5COOMe, it was only possible to determine the combined integrals for H-1 and
H-5COOMe (IH1+ICOOMe). This value can be introduced into the equation for the DE because the total
number of the H-5 protons is equal to the sum of the anomeric H-1 protons: ICOOMe + ICOO− = IH1.
The DE can be determined from DE (%) = [(ICOOMe + IH1) – ICOO−)/[(ICOOMe + IH1) + ICOO−)] × 100.
3.2.4. Determination of Intrinsic Viscosity ([η]) and Molar Mass Estimation of Pectin
The [η] (mL·g−1) of pectin solutions prepared in 100 mM NaCl (0.125, 0.250, 0.500, 1.000, 1.500
and 2.000 mg·mL−1) was measured as described in Section 3.2.2. The mean average molar mass, M,
was estimated from the [η] values using the Mark−Houwink equation (Equation (4)). The constants
used for pectin with a DE between 30.0–95.0%, were K = 9.55 × 10−2 (mL·g−1) and α = 0.73 [64].
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3.2.5. Preparation of Nano- and Microparticles
Chitosan Solutions
Chitosan solutions (5.0 mg·mL−1, w/v) were prepared in 5% stoichiometric excess of HCl and
in 100 mM NaCl by continuous magnetic stirring at room temperature (25 ± 1 ◦C) for 14 h, followed
by filtration through 5.0 µm membranes (EMD Millipore, Burlington, MA, USA). The ζ-potential of
the chitosan solutions (5.0 mg·mL−1, w/v) was measured by mixed laser Doppler velocimetry and
phase analysis light scattering (M3–PALS). A Malvern Zetasizer Nano ZS (Malvern Instruments Ltd.,
Worcestershire, UK) fitted with a red laser light (λ = 632.8 nm) was used. The ζ-potential was measured
at pre-determined intervals over the pH range 1.0–8.0, to assess the best conditions to obtain nano-
and microparticles. Triplicate measurements were performed.
Pectin Solutions
Pectin solutions (5.0 mg·mL−1, w/v) were prepared in 100 mM NaCl by continuous magnetic
stirring at 50 ± 1 ◦C for 1 h (to ensure the pectin would be solubilised) and then at room
temperature (25 ± 1 ◦C) for 13 h, followed by filtration through 5.0 µm membranes (EMD Millipore).
The ζ-potentials of the pectin solutions (5.0 mg·mL−1, w/v) was measured as described in the
previous section.
Pectin Purification
This was done according to Bernabé et al. [65]. Briefly, pectin (2.0 g·L−1) was dissolved in 50 mM
NaCl by continuous magnetic stirring at 50± 1 ◦C for 1 h and then, at room temperature (25± 1 ◦C) for
13 h. This solution was filtered successively through glass wool, sintered glass filters (pore diameters
of 80.0, 60.0, 40.0 and <10.0 µm) and membranes (5.0, 1.2, 0.8, 0.45 and 0.2 µm, EMD Millipore).
The polysaccharide was precipitated by gradual addition of ethanol until a final 80.0% (v/v) alcohol
concentration was obtained. The precipitate was removed by centrifugation (Sorvall, R-5 plus model,
Langenselbold, Germany) at 7000 rpm, 10 ◦C for 30 min. The solid was washed with ethanol/water
mixtures (70/30, 80/20, 90/10 and 100/0) for 5 min each. The purified polymer was dried at room
temperature (25 ± 1 ◦C) for 48 h.
3.2.6. Preparation of Nano- and Microparticles
Nano- and microparticles were prepared by electrostatic self-assembly according to the method
reported by Fuenzalida et al. [66]. Briefly, chitosan-pectin mixed systems were prepared at 0.10, 0.25,
0.50, 0.75, 1.00, 1.33, 2.00, 4.00 and 5.00 charge equivalent ratios (equiv. × L−1) (n+/n−), and 1.0 × 10−6
and 2.0 × 10−6 M total charge (n+ + n−). The formation and optimal conditions to obtain nano- and
micro-particles were screened by preparing the mixtures in a 96-well microplate (final volume 250 µL).
An appropriate aliquot of chitosan solution (5.0 mg·mL−1, w/v) was added into each microwell.
An aliquot of mixed pectin (5.0 mg·mL−1, w/v) and NaCl (100 mM) was added into the chitosan
solution and mixed thoroughly by flushing the mixture in and out of the pipette tip. The conversion
of the final solution (chitosan + pectin + NaCl) from a clear/limpid to turbid/opalescent appearance,
was taken as preliminary evidence of nanoparticle formation. When necessary, isolated nano- and
micro-particles solutions were obtained by centrifugation (10,000× g, 20 ◦C for 40 min) using Eppendorf
tubes containing 15 µL of glycerol. The pellets were re-suspended in 100 µL of 100 mM NaCl.
Insulin-loaded nano- and microparticles were prepared by considering the best charge ratios
(n+/n− 0.25 and 5.00) and total equiv. charge (1.0 × 10−6 M) results. A portion (30.0%) of the charges
of one polymer was substituted with insulin charges. Insulin (5.0 mg·mL−1) was dissolved in one of
the following solutions: 10 mM NaOH/100 mM NaCl (charge ratio (n+/n−) 0.25) or 100 mM NaCl,
pH adjusted to 2.70 (charge ratio (n+/n−) 5.00).
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3.2.7. Zeta-potential and Particle Size Determination of Nano- and Microparticles
Nano- and microparticles suspensions were prepared at charge ratios (n+/n−) 0.25 and 5.00,
1.0 × 10−6 total charge and in 100 mM NaCl solution. The particle size distribution was obtained
by dynamic light scattering with non-invasive back scattering (DLS-NIBS) at 173◦ with automatic
gain using a Malvern Zetasizer Nano ZS. The ζ-potential was measured as mentioned previously.
All measurements were recorded in triplicate at 25 ± 2 ◦C.
3.2.8. Production Yield
Nano- and microparticles, produced with and without insulin, were centrifuged (20 ◦C, 10,000× g,
40 min). The supernatant was removed, and the pellets were frozen at −20 ◦C and lyophilised for 48 h.
The production yield of the particles was calculated from the masses of chitosan, pectin, insulin (or not)
and NaCl used in the initial suspension preparation and the mass of the pellet formed (Equation (5)):
Yield (%) =
Mpellet(
Mc + Mp + Mins + MNaCl
) × 100 (5)
where, Mpellet is the mass of particles obtained after lyophilised process and Mc, Mp, Mins and MNaCl
are the respective initial masses of chitosan, pectin, insulin and sodium chloride used for nano- and
microparticles formation.
3.2.9. Stability Tests
The colloidal stability of the systems was assessed as described elsewhere [67]. Briefly, the isolated
nano- and microparticle solutions were incubated in 150 mM NaCl (adjusted pH to 7.4 using 0.1 M
NaOH and 0.1 M HCl), MEM (pH 7.4), SGF (pH 1.2) and SIF (pH 6.8) in a microtiter plate incubator
(Titramax model, Heidolph, Schwabach, Germany) at 37 ± 0.1 ◦C. At pre-determined times (0, 20,
40 60, 90, 120, and 180 min, and 24 h) the particle size distribution was measured by DLS-NIBS as
described in Section 3.2.7.
SGF solution. NaCl (0.4 g) was solubilised in 180 mL of deionised water and adjusted to pH 1.2
using 0.1 M NaOH and 0.1 M HCl. After, the final volume was made up to 200 mL. The pH was 1.2.
SIF solution. H2KPO4 (1.36 g) was dissolved in 50 mL of deionised water. Separately, 15.4 mL of
0.2 M NaOH and 100 mL of deionised water were combined. The solutions were homogenised together
and adjusted to pH 6.8 using 0.1 M NaOH and 0.1 M HCl. After, the final volume was made up to
200 mL. The pH was 6.8. Both the SGF and SIF solutions were prepared according to the United States
Pharmacopeia XIX.
3.2.10. Insulin Encapsulation Efficiency
The insulin EE in the different systems was determined using the protocol described by Marschütz
and Bernkop-Schnürch [68], as modified by Krauland and Alonso [69]. The supernatant obtained
after isolation was filtered (0.22 µm, Millipore) and then a 5.0 µL aliquot injected into a HPLC system
(model X-LC, Jasco, Easton, PA, USA) equipped with a peptide C18 reverse phase column (Aeris wide
pore XB-C18, 3.6 µm 150 × 2.1 mm, Phenomenex, Aschaffenburg, Germany) at room temperature
(25 ◦C). Gradient elution was performed as follows: 0.3 mL·min−1 flow rate for the first 5 min; linear
gradient from 70.0% A/30.0% B to 39.0% A/61.0% B (eluent A: 0.1% trifluoracetic acid in water; eluent
B: acetonitrile). Insulin and/or degradation products were detected at λ = 220 nm with a UV-Vis
detector. Insulin concentrations were quantified from integrated peak areas and calculated using a
calibration curve. The EE of insulin was calculated from the following equation (Equation (6)):
Encapsulation e f f iciency (EE, %) =
Total Ins − FreeIns
TotalIns
× 100 (6)
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where, Total Ins is the total quantity of insulin used to load at nano- and microparticles and FreeIns is
the quantity of insulin not associated to the nano- and microparticles.
3.2.11. Transmission Electron Microscopy
Nano- and microparticles unloaded and loaded-insulin formulated using chitosan DA 28.8% at
two different charge ratios (n+/n−) (0.25 and 5.00) were visualized by TEM. To this end, 20µL of freshly
prepared samples were mixed with 20µL of 1% (w/v) uranyl acetate for negative staining. Afterwards
8µL of samples were deposited onto a copper grid covered with Formvar® film. Excess liquid was
blotted using filter paper. Images were captured using a JEM-1400 TEM (JEOL, Peabody, MA, USA)
operating at 100 kV. Images were processed on an AMT 1k CCD (AMT, Woburn, MA, USA) using
AMTV602 software (AMT, Woburn, MA, USA).
3.2.12. Cytotoxicity (MTT Assay)
Cell Culture
Caco-2-cells were cultured in 75 cm2 flasks using MEM supplemented with 10% foetal bovine
serum, 1% L-glutamine (200 mM) and 1% penicillin-streptomycin (10,000 units penicillin, 10,000 units
streptomycin in 0.9% NaCl). The cultures were maintained in a humid atmosphere at 37 ◦C with 5%
CO2 (Sanyo MCO-19AIC, Panasonic Biomedical Sales Europe BV, AZ, Etten-Leur, The Netherlands).
Cells from passages 43, 44, 46 and 50 were used for all experiments, which were carried out as
independent triplicates on different days. After reaching microscopic confluence, the cells were
washed with 10 mL PBS and trypsinised with 10 mL of 0.05% trypsin in EDTA (1×) buffer. After
detachment, 10 mL of MEM was added to the trypsin buffer. The cell suspension was centrifuged at
1000 rpm for 5 min (Rotina 420 R, Andreas Hettich GmbH, Tuttlingen, Germany). The excess medium
was removed, and the cell pellet was resuspended in 1 mL MEM. A 10 µL aliquot of the cell suspension
was diluted with 90 µL trypan blue, and the number of cells was counted with an improved Neubauer
chamber before seeding. The cells were sub-cultured by splitting at a 1:10 ratio.
MTT Assay
This assay was used to evaluate the cytotoxicity of the formulations and components. Briefly,
100 µL of cell suspension was transferred to each well of a 96-well tissue culture plate (~104 cells
per well or ~105 cells × mL−1) and allowed to attach for 24 h. The cells were washed twice with
supplement-free MEM before the sample was added and the cells were then incubated for 3 h. Nano-
and micro-particles prepared in different charge ratio (n+/n− 0.25 and 5.00) using chitosan with
different DA (15.0% and 28.8%) were isolated as detailed previously and re-suspended in 100 µL of
MEM. Aliquots (100 µL) were then placed into each well and incubated for 4 h. The samples were
removed and replaced with 100 µL supplement-free MEM. A MTT solution in PBS with thiazolyl blue
tetrazolium bromide (25 µL, 5.0 mg·mL−1) was added to each well. After 4 h, the medium was again
removed, and DMSO was added to dissolve the MTT formazan crystals. The plates were protected
against light during agitation at 100 rpm for 15 min in an orbital shaker (KS 4000i control model, IKA,
Staufen, Germany). After, the absorbance was measured at λ = 570 nm with a microplate reader (Safire,
Tecan AG, Salzburg, Austria). Positive (cell death using 100 µL of Triton X 4.0% (w/v)) and negative
(cell death using 100 µL of MEM without particles) controls were used to determine the relative cell
viability. Each concentration was studied in eight microplates, and the biological experiments were
carried out in triplicate [70].
3.2.13. Insulin Release: In Vitro Tests
Insulin release assays were performed according to Bagre et al. [43]. Chitosan of different DA
(15.0% and 28.8%) and pectin solutions were prepared to obtain isolated nano- and microparticles
loaded with insulin at charge ratio (n+/n−) 5.0 and total charge of 1.0 × 10−6. The nano- and
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microparticle dispersions (100 µL) were placed into Eppendorf tubes containing 900 µL of SIF or SGF
and maintained in an incubator (Titramax model, Heidolph) at 37 ± 1 ◦C. Aliquots were removed at
pre-determined times (0, 15, 30, 45, 60, 90 and 120 min) and the insulin content was determined as
described in Section 3.2.10. The insulin release experiments were carried out in triplicate.
3.3. Statistical Analysis
The data were appraised using the Statistica program version 7.0 (Statistica Inc., Palo Alto, CA,
USA). Differences between the means were detected by Tukey’s multiple comparisons test.
4. Conclusions
Pectin–chitosan nano- and microparticles were obtained by electrostatic self-assembly. The small
particle sizes, ranging from 240–1900 nm were amenable to encapsulate insulin. The optimal charge
ratio (n+/n−) for nano- and microparticles formation were 0.25 (excess of pectin charges) and 5.00
(excess of chitosan charges), which produced the highest product yield (maximum 33.8%). Insulin was
efficiently encapsulated (from 34.0–62.0%) into the particles due to a strong interaction between the
oppositely charged polysaccharides. Controlled insulin release occurred under SIF (pH 6.8) conditions,
and less than 13.0% was released in SGF (pH 1.2, 2 h). The non-cytotoxicity (using chitosan with DA
15.0%) of the proposed system seems to be advantageous due to its simple manufacture, offering
an alternative route for oral insulin delivery with good stability under acidic (stomach) and basic
(intestinal) conditions.
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